Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine vs lamivudine in decompensated chronic hepatitis B with cirrhosis
2004-000443-17Phase 3Completed
- Sponsor
- Idenix Pharmaceuticals
- Start
- Sep 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB), Cirrhosis and hepatic failure comparing Telbivudine with Lamivudine (2 arms). Primary endpoint: Clinical Response (primary composite endpoint). Started Sep 2004; status: completed.
02
Drugs
telbivudinelamivudine
03
Conditions
Chronic Hepatitis B (CHB)Cirrhosishepatic failure
Beyond the preview
Go deeper on 2004-000443-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000443-17.